| CHONG-KUN-DANG-PHARMACEUTICALS-CORP |
CHONG-KUN-DANG-PHARMACEUTICALS-CORP |
85%
|
obligation amounted to $ 1,581 and $ 1,986 , respectively and are presented under deferred revenues. During the year ended December 31, 2025, the Company recognized revenues in the amount of $ 405 wh… |
| EWOPHARMA-AG |
EWOPHARMA-AG |
85%
|
obligation amounted to $ 1,581 and $ 1,986 , respectively and are presented under deferred revenues. During the year ended December 31, 2025, the Company recognized revenues in the amount of $ 405 wh… |
| EYE-FITE-LTD |
EYE-FITE-LTD |
85%
|
we granted an exclusive license for the use of our Piclidenoson drug candidate in the ophthalmic field, or the License Agreement, to Eye-Fite Ltd., an Israel limited company, or Eye-Fite |
| GEBRO-HOLDING-GMBH |
GEBRO-HOLDING-GMBH |
85%
|
obligation amounted to $ 1,581 and $ 1,986 , respectively and are presented under deferred revenues. During the year ended December 31, 2025, the Company recognized revenues in the amount of $ 405 wh… |
| NVO |
Novo Nordisk A/S |
72%
|
Reciprocal relationship from NVO graph: Reciprocal relationship from CANF graph: Reciprocal relationship from NVO graph: Reciprocal relationship from CANF graph: Reciprocal relationship from NVO grap… |
| NVO |
Novo Nordisk A/S |
72%
|
elopment of, facilities to manufacture a sufficient supply of our product candidates. We do not have the resources, facilities or experience to manufacture our product candidates for commercial purpo… |
| ORANY |
ORANY |
72%
|
e Public Health Service Act (IPHS) and the Federal Food, Drug, and Cosmetic Act (FDCA), as amended, and the regulations promulgated thereunder, and other federal and state statutes and regulations go… |
| ORANY |
ORANY |
72%
|
Reciprocal relationship from ORANY graph: Reciprocal relationship from CANF graph: Reciprocal relationship from ORANY graph: Reciprocal relationship from CANF graph: e Public Health Service Act (IPHS… |
| AFFILIATION-DR-KIM-PAPP-HEAD-PROBITY-MEDICAL-RES |
AFFILIATION-DR-KIM-PAPP-HEAD-PROBITY-MEDICAL-RES |
62%
|
ne. Manufacturing We are currently manufacturing our API through a leading CRO. The relevant suppliers of our drug products are compliant with both current Good Manufacturing Practices, or cGMP, and … |
| CAN-FITE-TECHNOLOGIES-LTD |
CAN-FITE-TECHNOLOGIES-LTD |
62%
|
o extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices such as promotion of products by medical practitioners. The EU Member State… |
| CV-THERAPEUTICS-INC |
CV-THERAPEUTICS-INC |
62%
|
elopment of, facilities to manufacture a sufficient supply of our product candidates. We do not have the resources, facilities or experience to manufacture our product candidates for commercial purpo… |
| DENALI-CONCRETE-MANAGEMENT-INC |
DENALI-CONCRETE-MANAGEMENT-INC |
62%
|
o extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices such as promotion of products by medical practitioners. The EU Member State… |
| F-D-CONSULTING-LTD-EYE-FITE-LTD |
F-D-CONSULTING-LTD-EYE-FITE-LTD |
62%
|
ice of each deliverable which is based on the Estimated Selling Price. Our contracts generally include three contract obligations: (i) performing the research and development services through regulat… |
| KYONGBO-PHARM-CO-LTD |
KYONGBO-PHARM-CO-LTD |
62%
|
for example, increased rebates for drugs subject to the Medicaid Drug Rebate Program, extension of Medicaid rebates to Medicaid managed care plans, mandatory discounts for certain Medicare Part D ben… |
| NORDISK-ROCHE-GSK-SAGIMET-BIOSCIENCES-INVENTIVA- |
NORDISK-ROCHE-GSK-SAGIMET-BIOSCIENCES-INVENTIVA- |
62%
|
elopment of, facilities to manufacture a sufficient supply of our product candidates. We do not have the resources, facilities or experience to manufacture our product candidates for commercial purpo… |
| NYSE-AMERICAN-COMPANY |
NYSE-AMERICAN-COMPANY |
62%
|
be unable to protect the intellectual property rights of the third parties from whom we license certain of our intellectual property or with whom we have entered into other strategic relationships. ●… |
| OPHTHALIX-BUFIDUCK-LTD |
OPHTHALIX-BUFIDUCK-LTD |
62%
|
o extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices such as promotion of products by medical practitioners. The EU Member State… |
| PASSIVE-FOREIGN-INVESTMENT-COMPANY |
PASSIVE-FOREIGN-INVESTMENT-COMPANY |
62%
|
o extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices such as promotion of products by medical practitioners. The EU Member State… |
| PFE |
Pfizer Inc. |
62%
|
Reciprocal relationship from PFE graph: Reciprocal relationship from CANF graph: ne. Manufacturing We are currently manufacturing our API through a leading CRO. The relevant suppliers of our drug pro… |
| PFIZER-HOECHST-MARION-ROUSSEL-INC |
PFIZER-HOECHST-MARION-ROUSSEL-INC |
62%
|
ne. Manufacturing We are currently manufacturing our API through a leading CRO. The relevant suppliers of our drug products are compliant with both current Good Manufacturing Practices, or cGMP, and … |
